Robert Klinestiver, MD
Pulmonary Disease · Greenfield, INNPI 1851383012
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,441 of the $12,984 with a category attached, or 88.1%. It is spread thinly across 49 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,519, 3.2 times the $1,402 reported in 2019.
Across 565 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$1K
- Intuitive Surgical$900
- Regeneron Healthcare Solutions, Inc.$806
- Grifols USA, LLC$767
- Sanofi$655
- plus $6K from 43 others
What the payments were for
- Travel & lodging$1,28910%
- Food & beverage$11,44188%
- Education$2542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,984 in reported general payments places this provider in the 80th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 358 | $374,814 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 147 | $112,311 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 99 | $76,278 |
| Spiriva RespimatTiotropium Bromide | 103 | $66,848 |
| Breo ElliptaFluticasone/Vilanterol | 74 | $51,813 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $43,467 |
| Spiriva HandihalerTiotropium Bromide | 30 | $26,081 |
| Tiotropium Bromide | 22 | $18,733 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 56 | $16,532 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $15,429 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $15,050 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $14,287 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 80 | $12,527 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $10,435 |
| DuleraMometasone/Formoterol | 15 | $9,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,277 | $480,529515 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $577 | $158,555223 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,788 | $133,833216 claims |
| MerckDulera | $30 | $9,34915 claims |
| PfizerAbrysvo | $138 | $3,50111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Greenfield
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.